Crystalys Secures $130 Million in Latest Series B Funding Round

Crystalys secured $130 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Crystalys Raises $130 million in Funding

Crystalys raised a $130M Series B to advance its de-risked gout therapy through phase 3 trials.

Investors Behind the Funding

The round was backed by undisclosed investors. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Crystalys operates in Healthcare & Life Sciences. Late-stage biotech financing remains strong for de-risked assets with clear phase 3 paths. Investors continue backing metabolic and inflammatory disease programs with large addressable patient populations.

Strategic Use of Funds

Fund phase 3 clinical development of its gout drug

Looking Ahead

Crystalys continues to attract investor attention following its latest financing.

Source reference: original announcement/article.